Halozyme Therapeutics (NASDAQ:HALO) Rating Increased to Strong-Buy at Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

A number of other brokerages have also commented on HALO. Citizens Jmp upped their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a research note on Tuesday, October 14th. Finally, Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $78.80.

Halozyme Therapeutics Trading Down 2.2%

Halozyme Therapeutics stock opened at $71.71 on Friday. Halozyme Therapeutics has a one year low of $47.50 and a one year high of $79.50. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a market cap of $8.43 billion, a PE ratio of 15.10, a price-to-earnings-growth ratio of 0.32 and a beta of 0.94. The stock has a 50-day moving average of $68.93 and a two-hundred day moving average of $68.36.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. Halozyme Therapeutics’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same period last year, the business earned $1.27 EPS. On average, research analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Helen Torley sold 16,569 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the completion of the sale, the chief executive officer owned 708,719 shares in the company, valued at $48,844,913.48. This represents a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 41,398 shares of company stock valued at $2,861,352 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently added to or reduced their stakes in the business. DLD Asset Management LP increased its position in shares of Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after acquiring an additional 5,000,000 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after acquiring an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 3.2% in the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock valued at $152,431,000 after purchasing an additional 63,699 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of Halozyme Therapeutics by 294.1% in the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after buying an additional 1,082,638 shares in the last quarter. Finally, LSV Asset Management boosted its stake in Halozyme Therapeutics by 0.9% in the third quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock valued at $92,850,000 after acquiring an additional 10,787 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer‑term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt‑on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell‑side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi‑year gains — useful context for longer‑term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near‑term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near‑term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.